CL Stock Overview
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
My Notes
NewNotes are coming soon
Cresco Labs Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$2.47 |
52 Week High | CA$10.36 |
52 Week Low | CA$2.29 |
Beta | 2.33 |
1 Month Change | -5.00% |
3 Month Change | -40.34% |
1 Year Change | -67.92% |
3 Year Change | -69.16% |
5 Year Change | n/a |
Change since IPO | -62.29% |
Recent News & Updates
Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet
Jan 25Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 24%?
Dec 13Recent updates
Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet
Jan 25Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 24%?
Dec 13We Think Cresco Labs (CSE:CL) Is Taking Some Risk With Its Debt
Aug 22Estimating The Intrinsic Value Of Cresco Labs Inc. (CSE:CL)
May 23Cresco Labs Inc. (CSE:CL) Analysts Are Way More Bearish Than They Used To Be
Mar 24Estimating The Fair Value Of Cresco Labs Inc. (CSE:CL)
Feb 02Cresco Labs Inc. (CSE:CL) Shares Could Be 41% Below Their Intrinsic Value Estimate
Oct 27Cresco Labs (CSE:CL) Takes On Some Risk With Its Use Of Debt
Oct 06Cresco Labs Inc. (CSE:CL) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates
Mar 27Breakeven Is Near for Cresco Labs Inc. (CSE:CL)
Mar 15The Cresco Labs (CSE:CL) Share Price Is Up 177% And Shareholders Are Boasting About It
Feb 22Calculating The Fair Value Of Cresco Labs Inc. (CSE:CL)
Feb 01Did Cresco Labs Inc. (CSE:CL) Insiders Sell Shares?
Jan 11What Type Of Shareholders Make Up Cresco Labs Inc.'s (CSE:CL) Share Registry?
Dec 25Does Cresco Labs (CSE:CL) Have A Healthy Balance Sheet?
Dec 07If You Had Bought Cresco Labs (CSE:CL) Shares A Year Ago You'd Have Earned 55% Returns
Nov 20News Flash: Analysts Just Made A Substantial Upgrade To Their Cresco Labs Inc. (CSE:CL) Forecasts
Nov 20Shareholder Returns
CL | CA Pharmaceuticals | CA Market | |
---|---|---|---|
7D | -4.3% | -3.5% | 0.7% |
1Y | -67.9% | -59.3% | -0.4% |
Return vs Industry: CL underperformed the Canadian Pharmaceuticals industry which returned -59.9% over the past year.
Return vs Market: CL underperformed the Canadian Market which returned -0.2% over the past year.
Price Volatility
CL volatility | |
---|---|
CL Average Weekly Movement | 12.9% |
Pharmaceuticals Industry Average Movement | 14.1% |
Market Average Movement | 9.9% |
10% most volatile stocks in CA Market | 19.5% |
10% least volatile stocks in CA Market | 3.9% |
Stable Share Price: CL is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: CL's weekly volatility (13%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | 3,300 | Charlie Bachtell | https://www.crescolabs.com |
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand, as well as cannabis products under the Reserve brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections, fruit-forward gummies, hard sweets, and taffy under the Mindy’s Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts.
Cresco Labs Inc. Fundamentals Summary
CL fundamental statistics | |
---|---|
Market Cap | CA$992.71m |
Earnings (TTM) | -CA$87.60m |
Revenue (TTM) | CA$1.13b |
0.7x
P/S Ratio-8.5x
P/E RatioIs CL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CL income statement (TTM) | |
---|---|
Revenue | US$842.04m |
Cost of Revenue | US$401.69m |
Gross Profit | US$440.35m |
Other Expenses | US$505.79m |
Earnings | -US$65.44m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.22 |
Gross Margin | 52.30% |
Net Profit Margin | -7.77% |
Debt/Equity Ratio | 51.8% |
How did CL perform over the long term?
See historical performance and comparison